Key result
In men with weight excess and hypertension, direct renin inhibition with aliskiren significantly increased effective renal plasma flow from 301 to 320 mL/min/1.73m2 and reduced mean arterial pressure compared to baseline.
Why the study?
Does direct renin inhibition with aliskiren improve renal and systemic hemodynamics and reduce RAAS activity compared to ACE inhibition with ramipril in men with weight excess and hypertension?
RCT (n=15)
Double-blind
1:1 cross-over
No
Does direct renin inhibition with aliskiren improve renal and systemic hemodynamics and reduce RAAS activity compared to ACE inhibition with ramipril in men with weight excess and hypertension?
In men with weight excess and hypertension, direct renin inhibition with aliskiren improved renal and systemic hemodynamics and reduced albuminuria, showing some distinct renal hemodynamic effects compared to ACE inhibition.
Answers are grounded in this paper and cite their sources.
Aliskiren improves renal hemodynamics in obese hypertensive men; extends ACEI comparisons by showing distinct renal effects.
AIM: The combination of weight excess and hypertension significantly contributes to cardiovascular risk and progressive kidney damage. An unfavorable renal hemodynamic profile is thought to contribute to this increased risk and may be ameliorated by direct renin inhibition (DRI). The aim of this trial was to assess the effect of DRI on renal and systemic hemodynamics and on RAAS activity, in men with weight excess and hypertension. METHODS: A randomized, double-blind, cross-over clinical trial to determine the effect of DRI (aliskiren 300 mg/day), with angiotensin converting enzyme inhibition (ACEi; ramipril 10 mg/day) as a positive control, on renal and systemic hemodynamics, and on RAAS activity (n = 15). RESULTS: Mean (SEM) Glomerular filtration rate (101 (5) mL/min/1.73m2) remained unaffected by DRI or ACEi. Effective renal plasma flow (ERPF; 301 (14) mL/min/1.73m2) was increased in response to DRI (320 (14) mL/min/1.73m2, P = 0.012) and ACEi (317 (15) mL/min/1.73m2, P = 0.045). Filtration fraction (FF; 34 (0.8)%) was reduced by DRI only (32 (0.7)%, P = 0.044). Mean arterial pressure (109 (2) mmHg) was reduced by DRI (101 (2) mmHg, P = 0.008) and ACEi (103 (3) mmHg, P = 0.037). RAAS activity was reduced by DRI and ACEi. Albuminuria (20 [9-42] mg/d) was reduced by DRI only (12 [5-28] mg/d, P = 0.030). CONCLUSIONS: In men with weight excess and hypertension, DRI and ACEi improved renal and systemic hemodynamics. Both DRI and ACEi reduced RAAS activity. Thus, DRI provides effective treatment in weight excess and hypertension. TRIAL REGISTRATION: Dutch trial register, registration number: 2532 www.trialregister.nl.
No takes yet. Share an insight, caveat, or question.
Kwakernaak et al. (2017) conducted an RCT in Weight excess and essential hypertension (n=15). Direct renin blockade (aliskiren) vs. Baseline and ACE inhibition (ramipril 10 mg/day) was evaluated on Effective renal plasma flow (ERPF) in mL/min/1.73m2 (p=0.012). In men with weight excess and hypertension, direct renin inhibition with aliskiren significantly increased effective renal plasma flow from 301 to 320 mL/min/1.73m2 and reduced mean arterial pressure compared to baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: